Robert Nelsen is a member of the board of directors at Encoded Therapeutics and a co-founder and managing director of ARCH Venture Partners. Mr. Nelsen also serves as a director of Vir Bio, GRAIL, Sana Biotechnology, Beam Therapeutics, Unity Biotechnology, Denali Therapeutics, Arivale, and serves as Chairman of Hua Medicine, among others.
Mr. Nelsen joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than 100 companies, including twenty-one which have reached valuations exceeding $1 billion. Some of his seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); and Juno Therapeutics (JUNO). He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and was a director of the National Venture Capital Association.
Mr. Nelsen holds an MBA from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.